Effective anti-PD-1 immunotherapy is associated with the presence of polyclonal CD8+ T cells in the tumour and blood specific for a limited number of immunodominant mutations, which are recurrently recognized over time.
- Cristina Puig-Saus
- Barbara Sennino
- Antoni Ribas